SciTech Development Raises $5.5 Million for Nanotechnology Cancer Drug Following 100% Disease Control Rate in T-Cell Lymphoma Trials
核心洞察
SciTech Development (搜索) successfully closed an oversubscribed $5.5 million funding round, exceeding its $3.0 million target by $2.5 million to advance cancer (搜索) clinical trials.
The company's lead drug candidate ST-001 nanoFenretinide (搜索) achieved an unprecedented 100% disease control rate at the highest dose levels in T-cell Non-Hodgkin Lymphoma (搜索) trials.
ST-001 demonstrated efficacy in both early- and late-stage cancer (搜索) patients with minimal side effects, leading most patients to continue trial participation.
SciTech Development (搜索), a clinical-stage oncology company, has successfully closed an oversubscribed $5.5 million convertible note funding round to advance its nanotechnology-enabled cancer (搜索) treatment platform. The round, which officially closed on September 5, 2025, exceeded its original $3.0 million target by $2.5 million, driven by exceptional interim clinical trial results for its lead drug candidate.
The strong investor response reflects confidence in ST-001 nanoFenretinide (搜索), the company's flagship drug currently undergoing evaluation in clinical trials for T-cell Non-Hodgkin Lymphoma (搜索) (T-cell NHL) across nine prestigious cancer (搜索) centers.
Unprecedented Clinical Results Drive Investment
ST-001 has achieved a remarkable 100% disease control rate at the highest dose levels administered to date. This means every patient treated at these levels has demonstrated either stable disease, partial responses, or is showing clear trajectory toward complete responses. Several patients have already experienced confirmed partial responses, marking a critical milestone toward potential complete recovery.
"This has truly been a breakout year for SciTech," said Earle Holsapple, CEO of SciTech Development (搜索). "The oversubscription of our CNR 3 underscores the confidence investors place in our science, our market position, and the transformative potential of ST-001. We are deeply grateful to both new and returning investors for their belief in our mission and support as we advance into the next phase of our trials."
Broad Therapeutic Potential and Safety Profile
The nanotechnology-enabled drug has demonstrated efficacy across both early- and late-stage cancer (搜索) patients, suggesting broad therapeutic potential for individuals battling this challenging disease. Beyond documented clinical activity at therapeutic doses, the trial has consistently confirmed ST-001's safety profile, validating the underlying scientific principles behind the drug's development.
Importantly, the majority of patients participating in the trial have reported only minimal side effects. This positive safety experience, combined with noticeable improvements in health and overall quality of life, has led most patients to willingly continue their participation in the trial.
Expanding Clinical Development Pipeline
The funding will enable SciTech to continue advancing clinical development in both T-cell NHL and Small Cell Lung Cancer (搜索) while building a foundation for future pipeline expansion. Andrew Stumpf, CFO of SciTech Development (搜索), noted that investors are motivated by the exceptional interim trial results and the proven strength of the company's team.
"Our new and returning investors are motivated by the exceptional interim trial results we've delivered and the proven strength of our team," Stumpf said. "This investment enables us to continue to advance clinical development in both T-cell NHL and Small Cell Lung Cancer (搜索), while building a strong foundation for our future pipeline."
Nanotechnology Platform Approach
SciTech Development (搜索) leverages its proprietary nanotechnology drug-delivery platform to develop ST-001 nanoFenretinide (搜索), positioned as a first-in-class drug currently in clinical trials for T-cell Non-Hodgkin Lymphoma (搜索). The company's patented design and proven potential suggest ST-001 may be applicable across a broad range of additional cancers, offering hope for more effective and accessible treatment options.